Stockreport

Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial

GENEREX BIOTECHNOLOGY  (GNBT) 
US:NASDAQ Investor Relations: generex.com/investor
PDF Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Conclus [Read more]